Rigel Ready To Hit The Ground Running After Early AML Drug Approval
Rezlidhia PDUFA Date Was Mid-February
Rezlidhia, which was only recently licensed by Rigal from Novo Nordisk-owned Forma Therapeutics, should challenge the market dominance of Servier's Tibsovo in the IDH-1 inhibitor subset of acute myeloid leukemia patients.
